Some men receive diagnoses for cancers that would never have caused them harm
A landmark synthesis of nearly 790,000 men's clinical data has placed an old medical dilemma in sharper relief: the PSA blood test, long debated, probably saves lives from prostate cancer and may reduce overall mortality, yet it also draws more men into a diagnostic net that catches cancers destined to cause no harm. The tension is not merely statistical — it is existential, asking whether knowledge of a silent disease is always a gift. In Latin America, where prostate cancer claims 61,000 lives each year and men often seek care only after the disease has advanced, the stakes of this unresolved question are especially human.
- A Cochrane review of six major trials has reignited urgent debate over whether PSA screening saves enough lives to justify the harms it sets in motion.
- For every 1,000 men screened, the test may prevent five deaths from any cause — a modest but real number that carries weight in regions where prostate cancer mortality is among the world's highest.
- The darker side of screening is overdiagnosis: men treated for slow-growing cancers that posed no threat face lasting consequences including incontinence, erectile dysfunction, and bowel complications.
- Latin America bears a disproportionate burden, with countries like Venezuela, Cuba, and Trinidad and Tobago ranking among global leaders in prostate cancer mortality, and Guatemala seeing diagnoses in men as young as 30.
- Newer screening methods combining biomarkers and imaging detect more cancers but cannot yet prove they save more lives, leaving clinicians and patients navigating the same unresolved trade-off.
A major review by Cochrane, the international body that synthesizes medical research, has analyzed six randomized trials involving nearly 790,000 men to revisit one of medicine's most contested questions: should men be routinely screened for prostate cancer with a PSA blood test?
The findings offer cautious encouragement. PSA screening probably reduces deaths from prostate cancer and may reduce overall mortality as well. Among every 1,000 men screened — ranging in age from 45 to 80 — the test might prevent five deaths from all causes combined. The numbers are modest, but in populations already carrying a heavy cancer burden, modest can still mean thousands of lives.
The evidence, however, carries a troubling counterweight. Screening increases diagnoses, particularly of early-stage disease, and some of those cancers would never have caused harm. This overdiagnosis pulls men into treatments — surgery, radiation — that can leave lasting damage: urinary incontinence, erectile dysfunction, bowel complications that persist long after the cancer is gone.
The stakes are especially acute in Latin America and the Caribbean, where prostate cancer strikes 226,000 men annually and kills roughly 61,000. Brazil and Argentina report incidence rates between 40 and 60 cases per 100,000 men. Guatemala has seen diagnoses in men as young as 30, with mortality projected to rise as the population ages. Venezuela, Cuba, and Trinidad and Tobago rank among the world's highest in prostate cancer death rates. Across much of the region, men tend to seek care only after the disease has advanced, narrowing their options.
Newer approaches combining standard blood tests with additional biomarkers and imaging detect more cancers, but researchers cannot yet confirm whether they actually save more lives. The fundamental tension endures: screening finds cancers early enough to matter, but also finds many that never would have. For men and their physicians, the decision to screen remains a wager on uncertainty — one that carries different weight depending on where in the world you live.
A sweeping review of clinical evidence has reignited an old debate about whether men should be screened for prostate cancer using a simple blood test. Researchers at Cochrane, an international collaboration that synthesizes medical research, analyzed six randomized trials involving nearly 790,000 men across Europe and North America to weigh the benefits and harms of PSA screening—a test that measures levels of a protein produced by the prostate gland.
The findings offer a measured case for screening. According to the analysis, PSA blood tests probably reduce deaths specifically from prostate cancer and could reduce overall mortality from any cause. The numbers are modest but meaningful: if 1,000 men undergo screening, the test might prevent five deaths from all causes combined, assuming a baseline risk of 491 deaths per 1,000 men over the study period. The men in these trials ranged from 45 to 80 years old.
Yet the same evidence reveals a troubling trade-off. Screening increases the number of men diagnosed with prostate cancer overall and, more significantly, with early-stage disease. This creates a cascade of consequences. Some men receive diagnoses and treatments for cancers that would never have caused them harm during their lifetime—a phenomenon researchers call overdiagnosis. The treatments themselves carry weight: surgery and radiation can trigger urinary incontinence, erectile dysfunction, and bowel problems that persist long after treatment ends.
The burden of prostate cancer falls unevenly across the world. In Latin America and the Caribbean, the disease claims roughly 61,000 lives annually among 226,000 newly diagnosed cases. Brazil and Argentina report incidence rates between 40 and 60 cases per 100,000 men. Guatemala has seen diagnoses climb in men as young as 30, with projections suggesting mortality will rise further by 2030 as the region's population ages. Venezuela, Trinidad and Tobago, and Cuba rank among the world's highest in prostate cancer mortality. In Mexico, the rate stands at 19.4 deaths per 100,000 men. Yet across much of the region, men often arrive at the doctor's office only after the cancer has advanced, limiting treatment options.
The Cochrane analysis leaves several questions unresolved. Newer screening approaches that combine standard blood work with additional biomarkers and prostate imaging appear to detect more cancers, but researchers cannot yet say whether these methods actually save lives. The core tension remains: screening catches some cancers early enough to matter, but it also catches many that would never matter at all. For men in their 50s and beyond, the choice to screen involves accepting that possibility—that a positive test might lead to treatment for a disease that posed no real threat.
The evidence suggests PSA screening is neither a clear win nor a clear loss. It probably reduces prostate cancer deaths and possibly reduces death from all causes, but at the cost of diagnosing and treating many men who would have lived their full lives without ever knowing they had the disease. In regions where prostate cancer already claims tens of thousands of lives each year, the question of who should be screened, and when, remains as contested as ever.
Citas Notables
PSA screening probably reduces prostate cancer deaths and could reduce overall mortality, but increases diagnoses of early-stage disease that may never cause harm— Cochrane systematic review analysis
Treatment side effects include urinary incontinence, erectile dysfunction, and bowel problems— Clinical evidence on prostate cancer treatment outcomes
La Conversación del Hearth Otra perspectiva de la historia
So the Cochrane review found that PSA screening saves lives. That sounds straightforward—why is this still controversial?
Because it saves some lives while creating problems for others. Five fewer deaths per 1,000 men is real, but screening also means more men get diagnosed with cancers that would never have hurt them. Those men then face surgery or radiation, which can leave them incontinent or impotent.
But if you don't know which cancers are dangerous and which aren't, how do you decide not to treat them?
Exactly. That's the bind. You can't know in advance. So screening casts a wide net, and some men caught in it didn't need to be.
The numbers from Latin America are striking—61,000 deaths a year. Does screening help there more than in Europe or North America?
That's the gap in the evidence. The trials were mostly European and North American. In Latin America, men often arrive at diagnosis when the cancer is already advanced. Earlier screening might help more there, but we don't have the data to say.
So the region with the highest burden of disease is also the region least studied?
Yes. Which means the men facing the highest risk are making decisions based on evidence gathered from populations with lower risk and better access to care.
What would change your mind about whether screening is worth it?
Evidence that newer screening methods—the ones using multiple biomarkers and imaging—actually reduce deaths without increasing overdiagnosis. Right now they catch more cancers, but we don't know if that translates to lives saved.